Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

26 Jan 2021

Field Trip Health Ltd. Announces Opening of Field Trip Health Center in Atlanta, GA, as it Continues Expansion in the US

ATLANTA, Jan....

By Microdose

Press Releases

26 Jan 2021

Pure Extracts Enters Into Biomass Purchase Agreements To Support Oil Extract Production

VANCOUVER, British Columbia, Jan....

By Microdose

Press Releases

26 Jan 2021

Psyched Wellness Included in First Psychedelic Exchange Traded Fund

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

26 Jan 2021

Havn Life Sciences Enters Definitive Agreement to Acquire Strategic Manufacturing & Packaging Facility for its Retail Division

The acquisition is intended to vertically integrate the Company’s retail manufacturing capabilities to support the growth of its nutraceutical division and deliver unique products to consumers....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

25 Jan 2021

PSYC Enters Joint Venture Partnership with Minerco, Inc.

PSYC Sets Sights on Expanding Its Digital Platform Within the Emerging Sector of Medicinal Psychedelics LAS VEGAS, NV, Jan....

By Microdose

Press Releases

25 Jan 2021

Ehave, Inc. Utilizes Artificial Intelligence and Machine Learning for Big Data Management in Mental Healthcare

MIAMI, Jan....

By Microdose

Press Releases

25 Jan 2021

Awakn Appoints James Collins, Ex-Accenture Strategy MD, as Chief Operating Officer

London, United Kingdom–(Newsfile Corp....

By Microdose

Press Releases

25 Jan 2021

Re-Release: Psyched Wellness Upsizes Previously Announced Bought Deal Offering

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

22 Jan 2021

Havn Life Grants Stock Options and Restricted Share Rights

Vancouver, BC – Havn Life Sciences Inc....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.